1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Egypt Pharmaceuticals and Healthcare Report Q1 2017

Egypt Pharmaceuticals and Healthcare Report Q1 2017

  • November 2016
  • -
  • Business Monitor International
  • -
  • 87 pages

Includes 3 FREE quarterly updates


>BMI View:
Multinational pharmaceuticals and healthcare companies will increasingly view Egypt as an attractive investment location. Increasing political will in Egypt to develop the healthcare sector has meant that a number of legislative changes aimed at both reducing market access barriers for foreign drugmakers and expanding access to medical services for the population have been enacted or announced for the future. That said, currency issues and an uncertain economic future ensure that Egypt will continue to present a high-risk investment opportunity for international drugmakers.

Headline Expenditure Projections

- Pharmaceuticals: EGP33.1bn (USD4.29bn) in 2015 to EGP35.6bn (USD4.0bn) in 2016; +7.6% in local currency terms and -7.9% in US dollar terms. Forecast in line with Q416.

- Healthcare: EGP125.9bn (USD16.3bn) in 2015 to EGP137.1bn (USD15.2bn) in 2016; +8.9% in local currency terms and -6.8% in US dollar terms. Forecast in line Q416. Egypt presents a moderately attractive commercial opportunity for multinational pharmaceutical companies. Egypt's medium-term growth is positive and has improved significantly over the past year in line with an improving political situation, albeit with persisting instabilities. In our Q117 Pharmaceutical Risk/Reward Index (RRI) Egypt's score of 38.3 out of 100 marks a slight decrease from its score of 44.3 in Q416, and moves below the regional average of 39.8. It is ranked as the fifth most attractive market in Africa, yet has lowered its position to 15th place out of 31 countries analysed in the whole Middle East and Africa (MEA) region. Egypt boasts a significantly large pharmaceutical market size compared to the majority of its regional peers; however, growth is hampered by below-average spending per capita on pharmaceuticals.

Table Of Contents

Egypt Pharmaceuticals and Healthcare Report Q1 2017
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Egypt 2014-2020) 7
SWOT 9
Industry Forecast 12
Pharmaceutical Market Forecast 12
Table: Pharmaceutical Sales, Historical Data And Forecasts (Egypt 2012-2020) 14
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Egypt 2012-2020) 17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Egypt 2012-2020) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Egypt 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Egypt 2012-2020) 19
Patented Drug Market Forecast 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Egypt 2012-2020) 21
Generic Drug Market Forecast 22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Egypt 2012-2020) 23
OTC Drug Market Forecast 24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Egypt 2012-2020) 25
Pharmaceutical Trade Forecast 26
Table: Pharmaceutical Trade Data And Forecasts (Egypt 2014-2020) 27
Table: Pharmaceutical Trade Data And Forecasts local currency (Egypt 2014-2020) 28
Industry Risk Reward Index 29
Middle East and Africa Risk/Reward Index - Q1 2017 29
Egypt Risk/Reward Index 37
Rewards 37
Risks 38
Regulatory Review 39
Intellectual Property Issues 39
Pricing Regime 41
Market Overview 44
Healthcare Sector 45
Table: Healthcare Resources (Egypt 2010-2015) 48
Table: Healthcare Personnel (Egypt 2010-2015) 48
Table: Healthcare Activity (Egypt 2010-2015) 49
Research and Development 49
Clinical Trials 50
Epidemiology 51
Competitive Landscape 56
Research-Based Industry 56
Table: Multinational Market Activity 59
Generic Drugmakers 60
Pharmaceutical Distribution 60
Pharmaceutical Retail Sector 61
Company Profile 62
Amoun Pharmaceutical Company (APC) 62
Egyptian International Pharmaceutical Industries Co (EIPICO) 65
Medical Union Pharmaceuticals (MUP) 69
South Egyptian Drug Industries (SEDICO) 71
VACSERA 74
Demographic Forecast 76
Demographic Outlook 76
Table: Population Headline Indicators (Egypt 1990-2025) 77
Table: Key Population Ratios (Egypt 1990-2025) 77
Table: Urban/Rural Population and Life Expectancy (Egypt 1990-2025) 78
Table: Population By Age Group (Egypt 1990-2025) 78
Table: Population By Age Group % (Egypt 1990-2025) 79
Glossary 81
Methodology 83
Pharmaceutical Expenditure Forecast Model 83
Healthcare Expenditure Forecast Model 83
Notes On Methodology 84
Risk/Reward Index Methodology 85
Index Overview 86
Table: Pharmaceutical Risk/Reward Index Indicators 86
Indicator Weightings 87

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.